<code id='BF1DD6FC7C'></code><style id='BF1DD6FC7C'></style>
    • <acronym id='BF1DD6FC7C'></acronym>
      <center id='BF1DD6FC7C'><center id='BF1DD6FC7C'><tfoot id='BF1DD6FC7C'></tfoot></center><abbr id='BF1DD6FC7C'><dir id='BF1DD6FC7C'><tfoot id='BF1DD6FC7C'></tfoot><noframes id='BF1DD6FC7C'>

    • <optgroup id='BF1DD6FC7C'><strike id='BF1DD6FC7C'><sup id='BF1DD6FC7C'></sup></strike><code id='BF1DD6FC7C'></code></optgroup>
        1. <b id='BF1DD6FC7C'><label id='BF1DD6FC7C'><select id='BF1DD6FC7C'><dt id='BF1DD6FC7C'><span id='BF1DD6FC7C'></span></dt></select></label></b><u id='BF1DD6FC7C'></u>
          <i id='BF1DD6FC7C'><strike id='BF1DD6FC7C'><tt id='BF1DD6FC7C'><pre id='BF1DD6FC7C'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:2
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          What we’ve learned from the Aduhelm mess
          What we’ve learned from the Aduhelm mess

          MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          PhRMA lawsuit over Medicare drug price negotiation tossed

          APStockWASHINGTON—AfederaldistrictjudgeonMondaygrantedtheBidenadministration’srequesttodismissalawsu